Patents by Inventor Stephen D. Barrett
Stephen D. Barrett has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9938289Abstract: The present invention provides for compounds of Formula I, and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, and R7 have any of the values defined therefor in the specification, and pharmaceutically acceptable salts thereof, that are useful as therapeutic agents in the treatment of TGF?-mediated conditions, including cancer and fibrotic disorders. Also provided are pharmaceutical compositions comprising one or more compounds of Formula I.Type: GrantFiled: January 14, 2016Date of Patent: April 10, 2018Assignee: FBM THERAPEUTICS, LLCInventors: Stephen D. Barrett, James B. Kramer, Mark L. Boys, Huifen Chen
-
Publication number: 20160200735Abstract: The present invention provides for compounds of Formula I, and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, and R7 have any of the values defined therefor in the specification, and pharmaceutically acceptable salts thereof, that are useful as therapeutic agents in the treatment of TGF?-mediated conditions, including cancer and fibrotic disorders. Also provided are pharmaceutical compositions comprising one or more compounds of Formula I.Type: ApplicationFiled: January 14, 2016Publication date: July 14, 2016Inventors: Stephen D. Barrett, James B. Kramer, Mark L. Boys, Huifen Chen
-
Patent number: 9260450Abstract: The present invention provides for compounds of Formula I, and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, and R7 have any of the values defined therefor in the specification, and pharmaceutically acceptable salts thereof, that are useful as therapeutic agents in the treatment of TGF?-mediated conditions, including cancer and fibrotic disorders. Also provided are pharmaceutical compositions comprising one or more compounds of Formula I.Type: GrantFiled: March 3, 2015Date of Patent: February 16, 2016Assignee: THESAN PHARMACEUTICALS, INC.Inventors: Stephen D. Barrett, James B. Kramer, Mark L. Boys, Huifen Chen
-
Patent number: 9090625Abstract: The present invention provides for compounds of Formula I, and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, and R7 have any of the values defined therefor in the specification, and pharmaceutically acceptable salts thereof, that are useful as therapeutic agents in the treatment of TGF?-mediated conditions, including cancer and fibrotic disorders. Also provided are pharmaceutical compositions comprising one or more compounds of Formula I.Type: GrantFiled: April 17, 2013Date of Patent: July 28, 2015Assignee: THESAN PHARMACEUTICALS, INC.Inventors: Stephen D. Barrett, James B. Kramer, Mark L. Boys, Huifen Chen
-
Publication number: 20150175624Abstract: The present invention provides for compounds of Formula I, and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, and R7 have any of the values defined therefor in the specification, and pharmaceutically acceptable salts thereof, that are useful as therapeutic agents in the treatment of TGF?-mediated conditions, including cancer and fibrotic disorders. Also provided are pharmaceutical compositions comprising one or more compounds of Formula I.Type: ApplicationFiled: March 3, 2015Publication date: June 25, 2015Inventors: Stephen D. Barrett, James B. Kramer, Mark L. Boys, Huifen Chen
-
Patent number: 8901319Abstract: A process for the synthesis and purification of F-series prostaglandin compounds and synthetic intermediates used to prepare them. The synthetic intermediates are solid and may be purified by precipitation and therefore may form the representative F-series prostaglandin compounds such as latanoprost, bimatoprost, fluprostenol, cloprostenol, and substituted analogs therefrom in highly pure forms.Type: GrantFiled: October 16, 2009Date of Patent: December 2, 2014Assignee: Cayman Chemical Company, IncorporatedInventors: Gilles Chambournier, Andriy Kornilov, Hussein M. Mahmoud, Ivan Vesely, Stephen D. Barrett
-
Publication number: 20140031385Abstract: The present invention provides for compounds of Formula I, and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, and R7 have any of the values defined therefor in the specification, and pharmaceutically acceptable salts thereof, that are useful as therapeutic agents in the treatment of TGF?-mediated conditions, including cancer and fibrotic disorders. Also provided are pharmaceutical compositions comprising one or more compounds of Formula I.Type: ApplicationFiled: April 17, 2013Publication date: January 30, 2014Applicant: Medicis Phamaceutical CorporationInventors: Stephen D. Barrett, James B. Kramer, Mark L. Boys, Huifen Chen
-
Patent number: 8455512Abstract: The present invention provides for compounds of Formula I, and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, and R7 have any of the values defined therefore in the specification, and pharmaceutically acceptable salts thereof, that are useful as therapeutic agents in the treatment of TGF?-mediated conditions, including cancer and fibrotic disorders. Also provided are pharmaceutical compositions comprising one or more compounds of Formula I.Type: GrantFiled: May 20, 2011Date of Patent: June 4, 2013Assignee: Medicis Pharmaceutical CorporationInventors: Stephen D. Barrett, James B. Kramer, Mark L. Boys, Huifen Chen
-
Publication number: 20120283451Abstract: A process for the synthesis and purification of F-series prostaglandin compounds and synthetic intermediates used to prepare them. The synthetic intermediates are solid and may be purified by precipitation and therefore may form the representative F-series prostaglandin compounds such as latanoprost, bimatoprost, fluprostenol, cloprostenol, and substituted analogs therefrom in highly pure forms.Type: ApplicationFiled: October 16, 2009Publication date: November 8, 2012Inventors: Gilles Chambournier, Andriy Kornilov, Hussein M. Mahmoud, Ivan Vesely, Stephen D. Barrett
-
Patent number: 8063240Abstract: A prostaglandin analog with selectivity to EP receptors and demonstrating EP agonist activity that may be used to expand hematopoietic stem cell populations or to treat or prevent influenza, bone fracture, bone disease, glaucoma, ocular hypertension, dysmenorrhoea, pre-term labor, immune disorders, osteoporosis, asthma, allergy, male sexual dysfunction, female sexual dysfunction, periodontal disease, gastric ulcer, renal disease, or other EP receptor-mediated conditions.Type: GrantFiled: November 14, 2008Date of Patent: November 22, 2011Assignee: Cayman Chemical Company, IncorporatedInventors: Nancy S. Barta, Stephen D. Barrett, Gregory W. Endres, Andriy M. Kornilov, Kirk M. Maxey, Adam Uzieblo
-
Publication number: 20110224251Abstract: The present invention provides for compounds of Formula I, and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, and R7 have any of the values defined therefor in the specification, and pharmaceutically acceptable salts thereof, that are useful as therapeutic agents in the treatment of TGF?-mediated conditions, including cancer and fibrotic disorders. Also provided are pharmaceutical compositions comprising one or more compounds of Formula I.Type: ApplicationFiled: May 20, 2011Publication date: September 15, 2011Applicant: Graceway Pharmaceuticals, LLCInventors: Stephen D. Barrett, Mark L. Boys, Huifen Chen, James B. Kramer
-
Patent number: 7964612Abstract: The present invention provides for compounds of Formula I, and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, and R7 have any of the values defined therefor in the specification, and pharmaceutically acceptable salts thereof, that are useful as therapeutic agents in the treatment of TGF?-mediated conditions, including cancer and fibrotic disorders. Also provided are pharmaceutical compositions comprising one or more compounds of Formula I.Type: GrantFiled: October 12, 2007Date of Patent: June 21, 2011Assignee: Graceway Pharmaceuticals, LLCInventors: Stephen D. Barrett, James B. Kramer, Mark L Boys, Huifen Chen
-
Publication number: 20090221654Abstract: A prostaglandin analog with selectivity to EP receptors and demonstrating EP agonist activity that may be used to expand hematopoietic stem cell populations or to treat or prevent influenza, bone fracture, bone disease, glaucoma, ocular hypertension, dysmenorrhoea, pre-term labor, immune disorders, osteoporosis, asthma, allergy, male sexual dysfunction, female sexual dysfunction, periodontal disease, gastric ulcer, renal disease, or other EP receptor-mediated conditions.Type: ApplicationFiled: November 14, 2008Publication date: September 3, 2009Applicant: CAYMAN CHEMICAL COMPANYInventors: Nancy S. Barta, Stephen D. Barrett, Gregory W. Endres, Andrei M. Kornilov, Kirk M. Maxey, Adam Uzieblo
-
Patent number: 5534522Abstract: The [1:1] maleate salt of [R-(Z)]-1-Azabicyclo [2.2.1]heptan-3-one, O-[3-(3-methoxyphenyl)-2-propynyl]-oxime, a known muscarinic agonist has unique properties relative to other salts of the compound, rendering it a desirable pharmaceutical.Type: GrantFiled: June 7, 1995Date of Patent: July 9, 1996Assignee: Warner-Lambert CompanyInventors: Howard Y. Ando, Stephen D. Barrett, Juan C. Jaen, Steven E. Rose, Haile Tecle
-
Patent number: 5346911Abstract: Pharmaceutically useful nitrogen containing cyclic oxime and amine substituted compounds which are azabicyclo[2.2.1]oximes, azabicyclo[2.2.2]oximes, azabicyclo[2.2.1]amines, azabicyclo[2.2.2]amines, azabicyclo[3.2.1]oximes, and amine containing heterocyclic oximes wherein the heterocyclic ring contains from 3 to 7 carbon atoms are disclosed.Type: GrantFiled: August 24, 1993Date of Patent: September 13, 1994Assignee: Warner-Lambert CompanyInventors: Corinne E. Augelli-Szafran, Stephen D. Barrett, Bradley W. Caprathe, Adam A. Galan, Juan C. Jaen, David J. Lauffer, Walter H. Moos, Michael R. Pavia, Kathryn B. Sanders, Haile Tecle, Anthony J. Thomas
